Regulatory T cell induction through delivery of immunosuppressive molecules

Regulatory T cell induction through delivery of immunosuppressive molecules refers to a strategy used to expand or activate regulatory T cells (Tregs), a subset of CD4+ T lymphocytes specialized in maintaining immune tolerance and suppressing excessive immune responses. Treg induction can be achieved by delivering cytokines such as TGF-β, IL-10, or IL-35, by using drugs that favor Treg expansion (e.g., rapamycin), or by manipulating cell surface receptor signaling pathways (such as CTLA-4 and CD25/IL-2R)[1][3][5][7]. This approach is used in the context of autoimmune diseases, transplantation, cancer, and infectious diseases to modulate immune responses and prevent tissue damage due to unwanted or excessive immunity. This "target" is not a specific molecule but rather a therapeutic paradigm leveraging several molecular pathways and cell surface receptors to achieve immunomodulation. Experimental and clinical strategies vary, and safety concerns are prominent due to risks of generalized immunosuppression[4][7].

Other names

Regulatory T cell inductionTreg inductionInduced regulatory T cell generation

Promotion of Treg differentiation or expansion through signaling of immunosuppressive cytokines (TGF-β, IL-10, IL-35) Pharmacological induction of immunosuppressive environment (e.g. rapamycin) Blockade or depletion of effector T cell activity to favor Treg activity Engagement of surface receptors (CD25, CTLA-4, PD-1) to maintain immune tolerance and suppress effector responses